Literature DB >> 29098390

Errors in insulin treatment management and risk of lipohypertrophy.

Giuseppe Maria Pozzuoli1, Mario Laudato2, Maria Barone2, Franco Crisci3, Bianca Pozzuoli3.   

Abstract

AIMS: Lipohypertrophy (LH) represents the most common skin-related complication associated with insulin therapy. Our aim is to estimate the prevalence of LH among insulin-treated patients, to identify its association with errors in insulin injection technique and storage, and the correlation between LH, risk of hypoglycemia, and glycemic control.
METHODS: Consecutive patients with T1DM or T2DM, attending a diabetes clinic for a routine visit, were administered an anonymous questionnaire investigating the modalities of insulin injection, the correct use of pen device, insulin storage, and reported frequency of hypoglycemic episodes. The presence of LH was assessed by inspection and palpation of injection sites.
RESULTS: Overall, 352 patients were enrolled (mean age 68 ± 12 years, 43.2% males, 88.9% with T2DM, mean duration of insulin therapy 9.1 ± 8.6 years). The prevalence of LH was 42.9%. At multivariate analysis, the strongest correlates of LH were not spacing injections (OR 20.4; 95% CI 10.5-39.6) and not rotating the site of injection (OR 2.01; 95% CI 1.08-3.75). Increasing doses of insulin and longer duration of insulin therapy also increased the risk of LH. The presence of LH was associated with a 2.7 times higher risk of severe hypoglycemia. Higher daily insulin doses, lack of rotation of injection sites, and keeping insulin in use in the refrigerator were independent correlates of higher HbA1c levels.
CONCLUSIONS: Insulin injection technique is suboptimal in many patients, highlighting the need for improved patient education. Increasing the awareness of the importance of preventing lipohypertrophy and insulin injection errors represents an important tool to reduce the clinical, social, and economic burden of diabetes.

Entities:  

Keywords:  Hypoglycemia; Insulin injection technique; Lipohypertrophy; Metabolic control

Mesh:

Substances:

Year:  2017        PMID: 29098390     DOI: 10.1007/s00592-017-1066-y

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Leveraging Mechanical Forces to Target Insulin Injection-Induced Lipohypertrophy and Fibrosis.

Authors:  Heather E desJardins-Park; Derrick C Wan
Journal:  Diabetes Spectr       Date:  2021-02-11

2.  Insulin-Related Lipohypertrophy: Lipogenic Action or Tissue Trauma?

Authors:  Anjana Barola; Pramil Tiwari; Anil Bhansali; Sandeep Grover; Devi Dayal
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-30       Impact factor: 5.555

3.  Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial.

Authors:  Liming Chen; Qiuling Xing; Jing Li; Jianxin Zhou; Yi Yuan; Ying Wan; Brian K Pflug; Kenneth W Strauss; Laurence J Hirsch
Journal:  Diabetes Ther       Date:  2021-02-11       Impact factor: 2.945

4.  Is skin disinfection before subcutaneous injection necessary? The reasoning of Certified Nurses in Infection Control in Japan.

Authors:  Yuko Yoshida; Risa Takashima; Rika Yano
Journal:  PLoS One       Date:  2021-01-08       Impact factor: 3.240

5.  A Systematic Survey of Physicians' Insights Into Lipohypertrophy.

Authors:  Min Shen; Yun Shi; Shuai Zheng; Hongqi Fan; Jingjing Xu; Tao Yang
Journal:  Front Public Health       Date:  2021-11-23

6.  The Impact of Insulin-Induced Lipodystrophy on Glycemic Variability in Pediatric Patients with Type 1 Diabetes.

Authors:  Fortunato Lombardo; Bruno Bombaci; Angela Alibrandi; Giulia Visalli; Giuseppina Salzano; Stefano Passanisi
Journal:  Children (Basel)       Date:  2022-07-20

7.  Quantitative evaluation of insulin-induced abdominal subcutaneous dystrophic tissue using shear wave elastography.

Authors:  Genki Sato; Hiroshi Uchino; Yosuke Shimizu; Junko Tatebe; Toshisuke Morita; Takahisa Hirose
Journal:  J Diabetes Investig       Date:  2022-02-11       Impact factor: 3.681

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.